Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease

Lupus

Volumn 27, Issue 3, 2018, Pages 399-406

  Erkan, D ^a   Unlu, O ^a   Sciascia, S ^b   Belmont, H M ^c   Branch, D Ware ^d   Cuadrado, M J ^e   Gonzalez, E ^f   Knight, J S ^g   Uthman, I ^h   Willis, R ^f   Zhang, Z ⁱ   Wahl, D ^j   Zuily, S ^j   Tektonidou, M G ^k  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^g UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^h AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

ⁱ PEKING UNIVERSITY FIRST HOSPITAL   (China)

^j UNIVERSITY HOSPITAL OF NANCY   (France)

^k UNIVERSITY OF ATHENS   (Greece)

more..

Author keywords

anticardiolipin antibodies; antiphospholipid antibodies; Antiphospholipid syndrome; hydroxychloroquine; lupus anticoagulant; primary thrombosis prevention; randomized controlled trial

Indexed keywords

ANTITHROMBOCYTIC AGENT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MORTALITY RATE; PRIORITY JOURNAL; THROMBOSIS; THROMBOSIS PREVENTION; ANTIPHOSPHOLIPID SYNDROME; BLOOD; CLINICAL TRIAL; COMPLICATION; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE; MULTICENTER STUDY; NEW YORK; PHASE 3 CLINICAL TRIAL; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; THROMBOCYTE;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD PLATELETS; ERYTHROCYTES; FEMALE; HUMANS; HYDROXYCHLOROQUINE; LINEAR MODELS; MALE; MIDDLE AGED; NEW YORK; PRIMARY PREVENTION; THROMBOSIS;

EID: 85042129382     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317724219     Document Type: Article

References (38)

1. Miyakis S, Lockshin MD, Atsumi T, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.
2. Erkan D, Harrison MJ, Levy R, Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 2007; 56: 2382–2391.
3. Kaiser R, Cleveland CM, Criswell LA. Risk and protective factors for thrombosis in systemic lupus erythematosus: Results from a large, multi-ethnic cohort. Ann Rheum Dis 2009; 68: 238–241.
4. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577–583.
5. Petri M. Lupus in Baltimore: Evidence-based “clinical pearls” from the Hopkins Lupus Cohort. Lupus 2005; 14: 970–973.
6. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997; 96: 4380–4384.
7. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: Effects on lipids, glucose and thrombosis. Lupus 19965 Suppl 1: S16–22.
8. Rand JH, Wu XX, Quinn AS, Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood 2010; 115: 2292–2299.
9. Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.
10. Erkan D, Lockshin MD. APS ACTION–AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Lupus 2012; 21: 695–698.
11. Barbhaiya M, Andrade D, Erkan D. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. Curr Rheumatol Rep 2016; 18: 64–64.
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.
13. Aletaha D, Neogi T, Silman AJ, 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
14. Shiboski SC, Shiboski CH, Criswell L, American College of Rheumatology classification criteria for Sjogren’s syndrome: A data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res 2012; 64: 475–487.
15. van den Hoogen F, Khanna D, Fransen J, 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2013; 65: 2737–2747.
16. ACR-endorsed Criteria for Rheumatic Diseases 2017, www.rheumatology.org/Practice-Quality/Clinical-Support/Criteria/ACR-Endorsed-Criteria (2017, accessed 1 July 2017).
17. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Eng Inform 2009; 42: 377–381.
18. Hereng T, Lambert M, Hachulla E, Influence of aspirin on the clinical outcomes of 103 anti-phospholipid antibodies-positive patients. Lupus 2008; 17: 11–15.
19. Ruffatti A, Del Ross T, Ciprian M, Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ann Rheum Dis 2009; 68: 397–399.
20. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: A 10 year follow-up of 52 patients. Lupus 1998; 7: 3–6.
21. Finazzi G, Brancaccio V, Moia M, Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: A four-year prospective study from the Italian Registry. Am J Med 1996; 100: 530–536.
22. Forastiero R, Martinuzzo M, Pombo G, A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost 2005; 3: 1231–1238.
23. Giron-Gonzalez JA, Garcia del Rio E, Rodriguez C, Rodriguez-Martorell J, Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: Prospective analysis of 404 individuals. J Rheumatol 2004; 31: 1560–1567.
24. Pengo V, Ruffatti A, Legnani C, Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: A multicenter prospective study. Blood 2011; 118: 4714–4718.
25. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 2002; 29: 2531–2536.
26. Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 2007; 16: 39–45.
27. Clark C, Spitzer K, Laskin C. Longterm follow-up of ASA/P trial participants: No evidence of thrombotic sequelae 20 years after antiphospholipid-associated recurrent pregnancy loss [abstract]. Arthritis Rheum 2009; 60: 1283–1283.
28. Erkan D, Merrill JT, Yazici Y, Sammaritano L, Buyon JP, Lockshin MD. High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. Arthritis Rheum 2001; 44: 1466–1467.
29. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: A case-control study. Hum Reprod 2005; 20: 1729–1732.
30. Silver RM, Draper ML, Scott JR, Lyon JL, Reading J, Branch DW. Clinical consequences of antiphospholipid antibodies: An historic cohort study. Obstet Gynecol 1994; 83: 372–377.
31. Hulley SB, Cummings SR, Browner WS, Grady DG, Newman TB. Designing clinical research, Philadelphia, PA: Lippincott Williams & Wilkins, 2013.
32. Guyatt G, Drummond R, Meade M, Cook D. The evidence-based medicine working group. In: Users’ guides to the medical literature. Essentials of evidence-based clinical practice. Chicago, IL: McGraw Hill Education, 2008
33. Clinical trials - Regulation EU No 536/2014, https://ec.europa.eu/health/human-use/clinical-trials/regulation_en (2014, accessed 9 March 2017)
34. Regulation (EU) No 536/2014 of The European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC, http://eur-lex.europa.eu/eli/reg/2014/536/oj (2014, accessed 9 March 2017)
35. Community register of orphan medicinal products, https://ec.europa.eu/health/documents/community-register/html/o1820.htm – top (2017, accessed 8 March 2017).
36. Committee for Orphan Medicinal Products (COMP) meeting report on the review of applications for orphan designation, www.ema.europa.eu/docs/en_GB/document_library/Committee_meeting_report/2016/12/WC500218368.pdf (2016, accessed 8 March 2017)
37. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10.
38. Zandvliet AS, Karlsson MO, Schellens JH, Copalu W, Beijnen JH, Huitema AD. Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents. Invest New Drugs 2010; 28: 61–75.